Adipiplon
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
NY (what is this?) (verify) |
Adipiplon (developmental code name NG2-73) is an anxiolytic drug developed by Neurogen Corporation. It has similar effects to benzodiazepine drugs, but is structurally distinct and classed as a nonbenzodiazepine anxiolytic.
Adipiplon is a subtype-selective GABAA receptor partial agonist, which binds preferentially to the α3 subtype. This is significant as while several previous nonbenzodiazepine drugs have been developed that are selective for α2/3 over the other subtypes, adipiplon is one of the first drugs selected for clinical development which can discriminate between α2 and α3, as well as showing a little affinity for the α1 or α5 subtypes — alpidem is selective for α3 over α2, but still has moderate affinity for α1, whereas adipiplon is highly α3-selective with little affinity for either α1, α2 or α5.
Adipiplon was being researched as a potential medication for the treatment of anxiety and insomnia, and in 2008 it was being used in Phase IIb trials.[1][2][3] These trials were suspended after significant next-day side effects were discovered.[4]
See also
References
GABAA |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GABAB | |||||||||||||||||||||||||
Antihistamines | |||||||||||||||||||||||||
Antidepressants |
| ||||||||||||||||||||||||
Antipsychotics |
Antidepressants | |
---|---|
Antipsychotics | |
Others |
- Agomelatine
- Melatonin
- Ramelteon
- Tasimelteon
- Cannabidiol
- Chlorophenylalkyldiols
- Diethylpropanediol
- Evoxine
- Fenadiazole
- Guaifenesin-related muscle relaxants
- Chlorphenesin
- Mephenesin
- Mephenoxalone
- Metaxalone
- Methocarbamol
- Midaflur
- Opioids (e.g., morphine)
- Passion flower
- Scopolamine
- Trazodone
- UMB68
- Valnoctamide
This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |